The Author Replies: Because of their inherent complexity and widespread distribution, medical devices will occasionally malfunction, fail, or cause unexpected adverse events. It is challenging to predict the longterm performance of implant ed devices on the basis of bench testing or pre marketing clinical trials of short duration. Thus, for selected lifesustaining products, postmarket ing studies of sufficient size and duration must be required of manufacturers. Unfortunately, when questions first arose about the performance of the Medtronic Sprint Fidelis ICD lead, the available postmarketing data were insufficient to allow an accurate evaluation of the device's performance. Over the ensuing months, tens of thousands of additional patients underwent im plantation of the lead, only to be notified of its recall a short time later.
There is no "deeper" problem than the un necessary exposure of patients to an underper forming permanently implanted medical device. Schultz outlines several important questions that must be answered in order to strengthen the deviceapproval and postmarketingmonitoring processes. In addition, technological advances such as remote, wireless device monitoring will, in some cases, facilitate collection of the needed performance data. More critical, however, is the need for a philosophical shift -from a medical device industry that primarily reacts to perfor mance failures to one that better anticipates them. 
Mechanical Ventilation and Disuse Atrophy of the Diaphragm
To the Editor: In their article, Levine et al.
(March 27 issue) 1 conclude that atrophy of the hu man diaphragm occurs with mechanical ventila tion; this finding is consistent with our observa tion of atrophy of the diaphragm in a patient with a high spinal cord injury after 8 months of mechanical ventilation necessitated by the failure of one diaphragmatic pacemaker. 2 In this pa tient, atrophy of the diaphragm was prevented in the hemidiaphragm connected to the function ing pacemaker by stimulating the pacemaker for only 30 minutes per day. Levine et al. speculate as to whether there are functional implications due to atrophy and whether strategies can be used to prevent atrophy. Our study addresses both of these questions. First, we found that atrophy was associated with profound reductions in tidal vol ume. Second, we found that stimulation of the phrenic nerve of the diaphragm for 30 minutes per day was sufficient to prevent atrophy. To the Editor: Levine and colleagues confirm that in the absence of respiratory effort, mechan ical ventilation for as little as 1 day causes pro found atrophy of the diaphragm in adult humans, as it does in animals. Two decades ago, Knisely and others 1 reported dramatic evidence of venti lationinduced atrophy in infants. They compared autopsy material obtained from 13 infants who died after mechanical ventilation for at least 12 days with that obtained from 26 infants who died after ventilation for 7 or days or less. Infants who were ventilated for a longer time had smaller dia phragm myofibers with histologic features of disuse atrophy, whereas strap and tongue mus cles appeared to be normal. 2 To control for the nutritional and catabolic effects of illness, they assessed ratios of the crosssectional areas of myofibers in the diaphragm to those of the strap or tongue muscle; both ratios were much lower among the subjects who were ventilated for a lon ger time. To the Editor: Levine and colleagues report on the effects of controlled mechanical ventilation on atrophy of the diaphragm. Although they cite other potential contributors to atrophy of the dia phragm (e.g., systemic inflammatory response syndrome and sepsis), they do not mention criti calillness polyneuropathy and myopathy and some of its risk factors, which also may lead to muscle atrophy and dysfunction of the diaphragm in these patients. 1 Criticalillness polyneuropathy and myopathy is common, with a prevalence rang ing from 30 to 90%, and it may develop quickly after the onset of critical illness. 2,3 Glycemic con trol may be an important strategy to mitigate criticalillness polyneuropathy and myopathy. 4 In this study, the blood glucose level was signifi cantly higher in case patients versus controls (164 vs. 92 mg per deciliter, P<0.001), and only 4 of 14 patients received insulin infusions. We posit a potential "twohit" hypothesis, with an interaction between muscle inactivity and the early development of subclinical criticalillness polyneuropathy and myopathy, contributing to rapid muscle atrophy in critically ill patients. This hypothesis requires investigation in future stud ies. Increasing awareness of criticalillness poly neuropathy and myopathy and further research on reversible risk factors and potential therapies are needed to ameliorate weakness and diaphrag matic dysfunction in critically ill patients. We also agree with Loring's comments about the article by Knisely et al. 2 Since their infant study subjects were not braindead, their observa tions provide support for our concept that brain death per se was not playing a major role in eliciting the myofiber atrophy observed in the diaphragms of our case subjects.
With regard to the comments by Heunks and Dekhuijzen, because of the lack of clinical and histologic data in the article by Sztark et al., 3 the mitochondrial dysfunction that they observed in the long peroneal muscle of their braindead organdonor subjects may represent early changes associated with disuse in this limb muscle. Sec ond, myosin concentration was not measured in our diaphragmbiopsy specimens. Therefore, in our predictions of the maximum forcegenerat ing capacity of the diaphragm, we used measured crosssectional areas, fibertype proportions, and assumed normal specific force for the diaphragm biopsy specimens from both case subjects and controls. If the increased proteolysis observed in the diaphragms of the case subjects was accom panied by a decrease in myosin concentration, as compared with the diaphragms of the controls, the diaphragms of the case subjects would have shown a greater decrease in forcegenerating capac ity than that estimated in our article (i.e., a de crease in transdiaphragmatic pressure of >55%).
We agree with Fan and Needham that our case subjects had hyperglycemia, which is a risk factor for both criticalillness polyneuropathy and myopathy. Therefore, these conditions should be considered as possible causes of atrophy of dia phragm myofibers. 4 The absence of necrosis and hypercellularity in the diaphragmbiopsy speci mens of our case subjects rules out the myopathy associated with the criticalillness polyneuropa thy and myopathy syndrome. 5 Since we did not obtain sections of phrenic nerve, we cannot rule out a neural contribution to the atrophy of dia phragm fibers observed in our case subjects.
Regarding the concerns of Leo and Spaggiari, we do not believe that either trauma or malnutri tion played a role in eliciting the atrophy of dia phragm fibers in the case subjects because we excluded subjects with thoracoabdominal trauma from our case cohort and because these patients showed no signs of malnutrition; indeed, our data indicate that case and control subjects did not differ with respect to bodymass index. 
